The authors in this multicenter, single-arm, open-label study evaluated the safety and efficacy of ibrutinib in 145 patients with relapsed or refractory del17p chronic lymphocytic leukemia (CLL). Overall response rate at 27.6 months was 83%. Additionally, 2-year progression-free and overall survivals were 63% and 75%, respectively. Grade 3 or worse infection rate was 30%.
The authors conclude that ibrutinib offers significant clinical benefit in the most difficult-to-control CLL subgroup, warranting continued study to better establish its position in treatment algorithms.
https://www.ncbi.nlm.nih.gov/pubmed/?term=27637985
